加载中
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
前收盘价
US$5.43
−US$0.65 · -10.69%
盘后
US$5.40
−US$0.03 · -0.55%
10月8日 16:58 ET
盘中时间采用ET。市场数据可能有所延迟。
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
日内区间
当前US$5.43
52周区间
当前US$5.43
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
91
深度低估
情绪
50
多空交织
风险
75
高风险
动量
24
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs designed to address conditions like diabetes, hypertension, and weight management. They also offer 'Dario Musculoskeletal' for preventing and treating common MSK conditions, and 'Dario' behavioral health solutions to improve access to evidence-based care. Their offerings extend to general chronic condition management solutions and DarioEngage, a proprietary care management platform. In terms of hardware, DarioHealth provides smart glucose meters, Bluetooth-connected blood pressure cuffs, digital scales, biofeedback sensor devices, and disposables such as test strip cartridges and lancets for blood glucose monitoring systems. Furthermore, they offer comprehensive diabetes management programs that integrate lifestyle changes, healthy eating guidance, advanced tracking tools, and live coaching. Founded in 2011, the company was formerly known as LabStyle Innovations Corp. before officially changing its name to DarioHealth Corp. in July 2016. Its headquarters are located in New York, New York.
日内区间
当前US$5.43
52周区间
当前US$5.43
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2235.9万 USD | 2704万 USD | 2035.2万 USD | 2765.6万 USD | 2051.3万 USD |
| 销货成本 | 969.4万 USD | 1377.3万 USD | 1436.8万 USD | 1800.1万 USD | 1244.4万 USD |
| 毛利 | 1266.5万 USD | 1326.7万 USD | 598.4万 USD | 965.5万 USD | 806.9万 USD |
| 研究与开发 | 1379.1万 USD | 2417.9万 USD | 2024.8万 USD | 1964.9万 USD | 1721.9万 USD |
| 销售、一般及管理费用 | 3552.9万 USD | 4683.2万 USD | 4179.7万 USD | 4681.6万 USD | 6235.8万 USD |
| 营业费用 | 4932万 USD | 7101.1万 USD | 6217.3万 USD | 6646.5万 USD | 8456.3万 USD |
| 利息收入 | 94.3万 USD | 111.6万 USD | 186.8万 USD | 50.6万 USD | 4.4万 USD |
| 利息支出 | 335.9万 USD | 9.6万 USD | 64.5万 USD | 268.3万 USD | 8.4万 USD |
| 折旧和摊销 | 313.8万 USD | 742.7万 USD | 498.5万 USD | 471.7万 USD | 445.7万 USD |
| 营业利润 | −3665.5万 USD | −5774.4万 USD | −5618.9万 USD | −5681万 USD | −7649.4万 USD |
| 净利润 | −4171.4万 USD | −4274.7万 USD | −5942.7万 USD | −6219.3万 USD | −7676.1万 USD |
公司数据更新于 2026年10月9日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.50
上涨空间 130.20%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年8月28日 | 1:20 | — | — |
股票拆分 | 2019年11月18日 | 1:20 | — | — |
股票拆分 | 2016年3月4日 | 18:1 | — | — |
股票拆分 | 2014年10月6日 | 5:1 | — | — |
已生效 2025年8月28日
1:20
已生效 2019年11月18日
1:20
已生效 2016年3月4日
18:1
已生效 2014年10月6日
5:1
报告持有此股票敞口的交易所交易基金。
Vanguard Extended Market ETFVXF48.4万0.00%954亿 USD0.05%US$233.13-0.15%
iShares Micro-Cap ETFIWC11.56万0.01%13.19亿 USD0.60%US$182.79-0.31%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR72960.00%453.77亿 USD0.17%US$84.07-0.04%
Dimensional - US Sustainability Core 1 ETFDFSU4541.760.00%23.79亿 USD0.15%US$47.88-0.08%
U.S. Micro Cap Portfolio ETFDFMC12160.00%75.44亿 USD0.43%US$57.70+0.35%Vanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Sustainability Core 1 ETFDFSUU.S. Micro Cap Portfolio ETFDFMCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
